key: cord-0715610-72kxtfcg
authors: Grupper, Ayelet; Katchman, Eugene; Ben‐Yehoyada, Merav; Rabinowich, Liane; Schwartz, Doron; Schwartz, Idit F.; Shashar, Moshe; Halperin, Tami; Turner, Dan; Goykhman, Yaacov; Shibolet, Oren; Levy, Sharon; Houri, Inbal; Baruch, Roni; Katchman, Helena
title: Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS‐CoV‐2 vaccine
date: 2021-09-29
journal: Clin Transplant
DOI: 10.1111/ctr.14478
sha: a210c50b5d0549d144a528b987e4eee5daa052d2
doc_id: 715610
cord_uid: 72kxtfcg

Majority of transplant recipients did not develop an appreciable humoral response following SARS‐CoV‐2 vaccine, in contrast to dialysis patients and healthy individuals. We analyzed the serologic response to BNT162b2 (Pfizer‐BioNTech) vaccine in a cohort of 19 kidney transplant recipients, vaccinated prior to transplantation, compare to 109 recipients vaccinated after transplantation, and to 39 healthcare workers, by determining the level of anti‐spike antibodies after transplantation. All controls and 17 of 19 (90%) of recipients vaccinated before transplant were seropositive, while only 49 of 109 (45%) recipients vaccinated post‐transplant had positive serology (P < .001). Median anti‐spike IgG in the group of kidney transplant recipients vaccinated after transplantation (10.7 AU/ml, [IQR 0–62.5]) was lower than the patients vaccinated before transplantation (66.2 AU/ml [21.6–138]), which was significantly lower than in the controls (156 AU/ml [99.7–215.5]). Negative humoral response was associated with vaccination post transplantation (odds ratio 22.4), older age (OR = 1.04), and longer time on dialysis (OR = 1.02), while higher lymphocyte count at time of vaccination was protective (OR = .52). Our findings of sustained superior humoral response to SARS‐CoV‐2 vaccine in kidney transplant recipients vaccinated prior to transplantation strongly support the recommendations of SARS‐CoV‐2 vaccination of transplant candidates, especially those younger than 60 years.

that, most end-stage renal disease (ESRD) patients on dialysis mount a serologic response to the mRNA vaccines, albeit they present lower post-vaccination antibody levels than healthy controls. 8, 9 The ideal timing of SARS-CoV-2 vaccination in the SOT setting is not known. The current recommendations of transplantation societies are to get vaccinated at least 2 weeks prior to transplantation. [10] [11] [12] However, data to support this approach in SARS-CoV-2 vaccines does not exist.

The present study was aimed to quantify the humoral response following full vaccination with the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine in a cohort of kidney transplant recipients, vaccinated at least 1 month prior to transplantation, by determining the level of antibodies directed against the S (spike) antigen after transplantation, and to compare it to kidney transplant recipients vaccinated after transplantation, and to immunocompetent vaccinated healthcare workers.

In order to eliminate cases with prior exposure to the virus and evaluate the effect of the vaccine itself, only participants with negative serology to SARS-CoV-2 nucleocapsid (N) protein were included.

Three cohorts were included in the study: Our group previously reported 6 For the detection of anti-SARS-CoV-2 antibodies we used the Dia-Sorin LIAISON SARSCoV-2 S1/S2 IgG serology assay, 13 which was validated previously. 14 Freshly collected blood in clot activator and gel tube was centrifuged at 4500 rpm for 10 min. The sera were separated and stored at 4 • C for analysis.

LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin S.p.A., Saluggia, Italy) was used according to the manufacture instructions, to detect IgG antibodies directed against a recombinant S protein (S1/S2). 13 Samples displaying < 12.0 AU/ml were considered negative, those ranging between 12.0 and 15.0 AU/ml are equivocal, and those > 15 AU/ml were considered as positive. For the purpose of the analysis, participants with equivocal response (a total of two participants) were considered as negative.

In addition, in order to explore prior exposure to SARS-CoV- was used for all statistical analyses. All participants in all cohorts were Caucasians except one liver and kidney recipient of East African (Ethiopian) origin.

As shown in Table 1 , no significant differences were observed between subjects in the three study groups with similar mean age as well as similar timing of the serum sampling post vaccination (Table 1) . However, the control group of healthcare workers had a higher percentage of females, and a lower prevalence of individuals with hypertension and diabetes, as compared to both transplant recipients' groups.

As expected, period of time following transplantation was significantly shorter in Pre-Tx Vac group. There was a similar rate of pre-emptive transplantations (without need for dialysis prior to kidney transplantation) in both groups. F I G U R E 2 Scatter plot of IgG anti S in participants who were seropositive in three study groups. Control group differed significantly from both recipients' groups, P < .001 

Data regarding response to SARS-CoV-2 vaccines are accumulating exponentially during the last months. Multiple studies found a robust serologic response to SARS-CoV-2 vaccine in healthy immunocompetent participants. 17, 18 Individuals with ESRD on chronic dialysis also show a significant serologic response, 8, 9 albeit lower than healthy controls. However, there is growing evidence that both humoral and F I G U R E 3 IgG anti S levels in three study cohorts subtracted to age groups of below and above 60 years cellular immune responses to SARS-CoV-2 vaccines are significantly reduced in kidney transplant recipients vaccinated after transplantation, compared to healthy controls and to ESRD patients. 19, 20 Our study, for the first time to the best of our knowledge, pro- in the previous studies 8, 9 and lower than in healthy controls.

Our results support the current recommendations of transplantation societies for the SOT candidates to get vaccinated against SARS-CoV-2 at least 2 weeks prior to transplantation, 10, 11 and reduce the concern that the diminished vaccine response in dialysis patients may become even more attenuated by post-transplantation

immunosuppression. 21 Previous studies demonstrated that the serological response to vaccination was related to the net burden of patients' immunosuppression. 6, 22, 23 In our study kidney recipients vaccinated before transplantation had significant levels of immunosuppression Advanced age was repeatedly defined as predictor for reduced antibody response in immunocompetent patients after COVID-19, 24 as well as after mRNA SARS-CoV-2 vaccination. 25, 26 Our finding indicates that even in immunosuppressed patients age remains an independent predictor of poor immunological response. In fact, in recipients older than 60 years, we could not find any advantage for the pre-transplantation vaccination.

mRNA SARS-CoV-2 vaccines, similar to other vaccines, are noted to cause mild to moderate side effects in immunocompetent individuals. 27 In our current study, as well as previous studies, 6, 28 the most common side effect was mild local pain, and none of the Based on our findings of a superior humoral response to the SARS-CoV-2 vaccine in the kidney transplant recipients vaccinated prior to transplantation, we strongly suggest to adopt this approach whenever possible, especially for transplant candidates younger than 60 years.

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

Is COVID-19 infection more severe in kidney transplant recipients?

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccines

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Humoral response to the pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis

Humoral response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis

SARS-CoV-2 Vaccination in Heart and Lung Transplantation: Recommendations from the ISHLT COVID-19 Task Force

American Society of Transplantation COVID-19 Vaccination Guidance

Guidance on Coronavirus Disease 2019 (COVID-19) for Transplant Clinicians

LIAISION®SARS-CoV-2 S1/S2 IgG package insert

Side-by-side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Improving global outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

An mRNA vaccine against SARS-CoV-2 -preliminary report

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Serologic vaccination response after solid organ transplantation: a systematic review

Influenza vaccination in the organ transplant recipient: review and summary recommendations

Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients

Sex, age and hospitalization drive antibody response in a COVID-19 convalescent plasma donor population

COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed

Safety and immunogenicity of SAR-CoV-2 mRNA vaccine in older adults

First month of COVID-19 vaccine safety monitoring-United States

Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation

Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine

The authors of this manuscript would to thank the Israeli minister of health for providing the LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay.

The authors declare no conflict of interests.

A. Grupper 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ayelet Grupper https://orcid.org/0000-0002-5590-9428